* Shares of drug developer Compass Pathways CMPS.O fall 35.4% to $2.99 premarket
** Co says its experimental psilocybin-based therapy helped significantly reduce the symptoms of difficult-to-treat depression in a late-stage study
** This was measured on a standardized depression scale after six weeks of treatment where the drug reduced depression by 3.6 points compared to a placebo
** However, investors were expecting a five point difference, brokerage RBC Capital Markets said in May
** Up to last close, stock had risen 22.5% YTD
Hier mein bester
bewegt sich null. Jemand da mehr in der Materie? Kursziele weit drüber. Ergebnisse Studie nicht so schlecht. Haben die noch mehr im Portfolio?
Paar
- Compass Pathways plc ADR long 2,04